Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
Checked against the public recordLast updated Aug 2, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- AstraZeneca
- Interventions being studied
- Drug: Gefitinib; Drug: AZD9291; Drug: Selumetinib+Docetaxel; Drug: Tremelimumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Provision of archived tumor tissue sample and mandatory tissue biopsy * Patients must have either histologically or cytologically documented NSCLC who present with locally advanced or metastatic stage IIIB-IV disease * Life expectancy ≥12 weeks * Patients must have measurable disease and at least 1 lesion not previously irradiated * World Health Organization (WHO) performance status of 0 or 1 Exclusion Criteria: * Mixed small cell and NSCLC histology * Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Research SiteGoodyear, Arizona
- Research SiteWashington D.C., District of Columbia
- Research SiteAugusta, Georgia
- Research SiteMarietta, Georgia
- Research SiteAshland, Kentucky
- Research SiteSt Louis, Missouri
- Research SiteMineola, New York
- Research SiteHuntersville, North Carolina
- Research SiteSpokane, Washington
- Research SiteTacoma, Washington
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 2, 2019. Always confirm current availability with the study team.